Vimarsana
Biggest News Aggregation in the World

Page 2 - Equity Subscription News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equity Subscription. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equity Subscription Today - Breaking & Trending Today

Nevada Copper Provides Update on the Proposed Restart - Vimarsana News

Nevada Copper Provides Update on the Proposed Restart

YERINGTON, Nev., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Nevada Copper (TSX: NCU) (OTC: NEVDF) (FSE: ZYTA) (“Nevada Copper” or the “Company”) is pleased to...

Nevada Copper Provides Update on Restart Activities at - Vimarsana News

Nevada Copper Provides Update on Restart Activities at

YERINGTON, Nev., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Nevada Copper (TSX: NCU) (OTC: NEVDF) (FSE: ZYTA) (“Nevada Copper” or the “Company”) is pleased to...

Nevada Copper Provides Update on Restart Activities at Pumpkin Hollow and the Proposed Restart Financing Package - Nevada Copper (OTC:NEVDF) - Press Release - Vimarsana News

Nevada Copper Provides Update on Restart Activities at Pumpkin Hollow and the Proposed Restart Financing Package - Nevada Copper (OTC:NEVDF) - Press Release

YERINGTON, Nev., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Nevada Copper NCU NEVDF ZYTA ("Nevada Copper" or the "Company") is pleased to provide an update on

AfriTin Mining's $48.3 million proposed funding package - Vimarsana News

AfriTin Mining's $48.3 million proposed funding package

AfriTin Mining has negotiated a potential funding package which could potentially finance the company’s existing operations at the Uis Mine in Namibia.

21st Austria weekly - Valneva; AT&S (20/06/2022) - Vimarsana News

21st Austria weekly - Valneva; AT&S (20/06/2022)

21st Austria weekly - Valneva; AT&S 20/06/2022 [pic1]Valneva: Austrian/French vaccine company Valneva and Pfizer announced that they have entered into an Equity Subscription Agreement updated the terms of their Collaboration License for Lyme disease candidate VLA15. As previously on April 26 2022 plans to initiate Phase 3 study VLA15 in third quarter 2022. part Agreement